Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of subretinal AAV2-REP1 gene therapy for choroideremia
NL-OMON47482Phase 3Active, not recruiting
- Sponsor
- Nightstar Therapeutics
- Start
- Dec 2018
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of timrepigene emparvovec in choroideremia (3 arms), sponsored by Nightstar Therapeutics. Primary endpoint: Proportion of subjects with at least 15-letter improvement in best corrected visual acuity at Month 12. Started Dec 2018; status: active, not recruiting.
02
Drugs
timrepigene emparvovec
03
Conditions
choroideremia
Beyond the preview
Go deeper on NL-OMON47482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47482.